Biophage Pharma awarded NRC-IRAP funding to develop next generation Biosensors


    MONTREAL, Jan. 15 /CNW Telbec/ - (TSX.V: BUG). Biophage Pharma Inc. today
announced that it has received confirmation of financial support from the
National Research Council Industrial Research Assistance Program (NRC-IRAP)
for the development of its next generation of PDS(R) Biosensors which will
rapidly and specifically detect life threatening pathogens like Methicillin
Resistant Staphylococcus Aureus (MRSA), Pseudomonas aeruginosa and
E. coli O157.
    These first targeted bacteria were chosen based on the urgency to
minimize the spread of hospital acquired infections and controlling
contamination in our food supplies. Hospital acquired infections are the
fourth leading cause of death in North America and within this category, MRSA
and Pseudomonas aeruginosa are the two most prevalent bacteria. On the other
hand, E. coli O157 is the leading cause of foodborne illness, causing severe
bloody diarrhea, and occasionally kidney failure (a life-threatening condition
mainly in immunosuppressed patients).
    "This financial support represents a cornerstone in our R&D program and
will enable us to accelerate the development of our next generation
biosensors. Our first generation, the PDS(R)16 biosensor, detects the total
bacterial load in a biological sample and the second generation of biosensors
will specifically detect MRSA, Pseudomonas and E. coli O157." said
Dr. Mandeville, President and CEO of Biophage Pharma Inc. "Presently, almost
all diagnostic techniques take between 8 to 16 hours, and our objective is to
provide an accurate diagnosis of these infections/contaminations in less than
5 minutes," added Dr Mandeville.

    About Biophage Pharma Inc.

    Biophage is a Canadian biotechnology company focused on the development
of innovative phage-based products and technologies for the detection,
prevention and control of bacterial infections. Biophage also operates the
Immunotox Labs division, which provides services in Immunogenicity and
Immunotoxicity, screening for Beryllium sensitization (the BeLPT test) and
exclusive MELISA(R) for the detection of sensitization to more than
200 different allergens including metals, penicillin, gluten, pollens and more
recently Lyme disease (Boreliosis).
    (www.biophagepharma.net; www.immunotoxlabs.com)

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.



For further information: Rosemonde Mandeville, M.B., Ch.B., PhD.,
President and CEO, Biophage Pharma Inc., (514) 496-1488,
rosemonde.mandeville@biophagepharma.net; Louis Guindon, Chief Financial
Officer, Biophage Pharma Inc., (514) 496-3230,
louis.guindon@biophagepharma.net